Inhibition of topoisomerase IIa: Novel function of wedelolactone

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Medicine. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

BENEŠ Petr KNOPFOVÁ Lucia TRČKA Filip NEMAJEROVÁ Alice PINHEIRO Diana SOUČEK Karel FOJTA Miroslav ŠMARDA Jan

Year of publication 2011
Type Article in Periodical
Magazine / Source Cancer Letters
MU Faculty or unit

Faculty of Science

Citation
Web http://www.sciencedirect.com/science/article/pii/S0304383511000127
Doi http://dx.doi.org/10.1016/j.canlet.2011.01.002
Field Genetics and molecular biology
Keywords Apoptosis; DNA damage; Proliferation; Topoisomerase; Wedelolactone
Description The naturally occurring coumestan wedelolactone has been previously shown to reduce growth of various cancer cells. So far, the growth-suppressing effect of wedelolactone has been attributed to the inhibition of the NFkB transcription factor and/or androgen receptors. We found that wedelolactone suppressed growth and induced apoptosis of androgen receptor-negative MDA-MB-231 breast cancer cells at concentrations that did not inhibit the NFkB activity. The cells responded to wedelolactone by the S and G2/M phase cell cycle arrest and induction of the DNA damage signaling. Wedelolactone interacted with dsDNA and inhibited the activity of DNA topoisomerase IIa. We conclude that wedelolactone can act as growth suppressor independently of NFkB and androgen receptors.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info